Actinium Pharmaceuticals, Inc. (ATNM)
- Previous Close
7.17 - Open
7.03 - Bid 6.75 x 1800
- Ask 7.40 x 800
- Day's Range
6.85 - 7.43 - 52 Week Range
4.00 - 9.86 - Volume
185,216 - Avg. Volume
363,872 - Market Cap (intraday)
204.599M - Beta (5Y Monthly) 0.08
- PE Ratio (TTM)
-- - EPS (TTM)
-1.83 - Earnings Date May 15, 2024 - May 30, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
25.47
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, Iomab-B (I-131 apamistamab) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for bone marrow transplant conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iomab-ACT for GeneTx and cell therapy conditioning, Actimab-A (CD33) and CLAG-M, Actimab-A (CD33) and Venetoclax, and Actimab-A (CD33) and Venetoclax with HMA. It has collaboration with Astellas Pharma, Inc. to develop theranostics for solid tumor indications; EpicentRx, Inc that focuses on a novel CD47 -SIRPa immunotherapy targeted radiotherapy; AVEO Oncology that focuses on developing a HER3 targeting ARC for solid tumors; and Immedica pharma for licensed the rights to commercialize Iomab-B. The company is based in New York, New York.
www.actiniumpharma.comRecent News: ATNM
Performance Overview: ATNM
Trailing total returns as of 4/23/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ATNM
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ATNM
Valuation Measures
Market Cap
210.77M
Enterprise Value
136.21M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.35k
Price/Book (mrq)
5.79
Enterprise Value/Revenue
1.68k
Enterprise Value/EBITDA
-2.66
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-33.17%
Return on Equity (ttm)
-94.92%
Revenue (ttm)
81k
Net Income Avi to Common (ttm)
-48.82M
Diluted EPS (ttm)
-1.83
Balance Sheet and Cash Flow
Total Cash (mrq)
76.68M
Total Debt/Equity (mrq)
5.81%
Levered Free Cash Flow (ttm)
-29.7M